359781-89-8

Upstream product

• 70671-51-1 N⁵-benzyloxycarbonyl-DL-ornithine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1070-19-5 N-(tert-butyloxycarbonyl) azide 

Downstream Products

• 70671-51-1 N⁵-benzyloxycarbonyl-DL-ornithine 
• 693222-15-0 [4-(4-benzyloxycarbonylamino-1-chloroacetyl-butylcarbamoyl)-4-tert-butoxycarbonylamino-butyl]-carbamic acid benzyl ester 
• 754185-59-6 (4-amino-6-chloro-5-oxo-hexyl)-carbamic acid benzyl ester 
• 693222-11-6 (4-tert-butoxycarbonylamino-6-chloro-5-oxo-hexyl)-carbamic acid benzyl ester 
• 872043-89-5 {4-[5-(3-benzyloxycarbonylamino-propyl)-6-methyl-3-oxo-3,4-dihydro-pyrazin-2-yl]-butyl}-carbamic acid benzyl ester 
• 872043-68-0 C₆₃H₈₀N₈O₁₁ 
• 872043-71-5 C₆₄H₈₂N₈O₁₁ 
• 501022-53-3 3,6-bis(3'-benzyloxycarbonylaminopropyl)-5-methyl-2(1H)-pyrazinone 
• 145622-67-9 2-Amino-5-benzyloxycarbonylamino-pentanoic acid benzyl ester 
• 359781-87-6 Nα-Isobutyl-Nδ-benzyloxycarbonyl-DL-ornithine Methyl Ester 
• 21887-64-9 N^α-(t-butoxycarbonyl)ornithine 

Relevant academic research and scientific papers

BIOMARKER PANEL TARGETED TO DISEASES DUE TO MULTIFACTORIAL ONTOLOGY OF GLYCOCALYX DISRUPTION

The present disclosure provides biomarkers useful as companion diagnostics for detecting glycocalyx-based disease that is amenable to treatment using compounds designed for improving the condition of the glycocalyx and/or reducing inflammation and/or oxidative damage, as well as related compositions, kits, and methods.

Inhibitors of nitric oxide biosynthesis

The present invention is a method of treating hypotension and shock using select ornithine or NG -arginine derivatives.